Piedmont Investment Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Piedmont Investment Advisors’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-3,228	Closed	-$200K	–	924
2019 Q3	$200K	Sell	3,228 -760	-19%	-$47.7K	0.01%	875
2019 Q2	$284K	Buy	+3,988	New	+$294K	0.01%	788
2018 Q4	–	Sell	-7,775	Closed	-$1.33M	–	1065
2018 Q3	$1.33M	Sell	7,775 -177	-2%	-$26.7K	0.06%	258
2018 Q2	$1.03M	Buy	7,952 +721	+10%	+$80.5K	0.05%	303
2018 Q1	$745K	Buy	7,231 +279	+4%	+$27.6K	0.02%	342
2017 Q4	$594K	Sell	6,952 -351	-5%	-$30.4K	0.01%	372
2017 Q3	$620K	Buy	7,303 +705	+11%	+$55.8K	0.01%	368
2017 Q2	$500K	Buy	+6,598	New	+$462K	0.01%	418

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Piedmont Investment Advisors's LGND Position: Q4 2019 in Review

Piedmont Investment Advisors sold out of Ligand Pharmaceuticals (LGND) in Q4 2019, closing a stake of 3,228 shares — an estimated $200K sold.

Piedmont Investment Advisors first reported a position in LGND in Q2 2017 and held it in 8 quarters. The position peaked at $1.33M in Q3 2018. 266 funds tracked by Wall St. Rank hold LGND as of Q4 2019.

Piedmont Investment Advisors reported no remaining Ligand Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Piedmont Investment Advisors sold 3,228 Ligand Pharmaceuticals shares in Q4 2019, an estimated $200K.
Piedmont Investment Advisors first reported a position in Ligand Pharmaceuticals in Q2 2017 and held it in 8 quarters.
Piedmont Investment Advisors's Ligand Pharmaceuticals position peaked at $1.33M in Q3 2018.
266 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2019.

Based on Piedmont Investment Advisors's 13F filing for Q4 2019, filed 11 Feb 2020.